Connect Biopharma Holdings Limited (CNTB): Price and Financial Metrics

Connect Biopharma Holdings Limited (CNTB): $0.65

0.06 (-8.43%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add CNTB to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#251 of 398

in industry

CNTB Price/Volume Stats

Current price $0.65 52-week high $1.58
Prev. close $0.71 52-week low $0.53
Day low $0.53 Volume 105,900
Day high $0.69 Avg. volume 253,301
50-day MA $0.90 Dividend yield N/A
200-day MA $1.02 Market Cap 35.89M

CNTB Stock Price Chart Interactive Chart >


Connect Biopharma Holdings Limited (CNTB) Company Bio


Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.


CNTB Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTB Latest Social Stream


Loading social stream, please wait...

View Full CNTB Social Stream

Latest CNTB News From Around the Web

Below are the latest news stories about CONNECT BIOPHARMA HOLDINGS LTD that investors may wish to consider to help them evaluate CNTB as an investment opportunity.

Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?

Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | September 15, 2023

Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update

Key data readouts with Company’s lead drug candidate rademikibart expected in the fourth quarter of 2023 Topline results from Stage 2 of the China pivotal trial in atopic dermatitisTopline results from Global Phase 2 trial in asthma Cash balance of $131.6 million expected to support planned operations into at least 2026 SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage

Yahoo | September 12, 2023

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that on September 11, 2023, it received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (

Yahoo | September 12, 2023

Connect Biopharma to Participate in Upcoming September Investor Conferences

SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Connect Biopharma’s management team will participate at the following upcoming investor conferences: H.C. Wainwright 25th

Yahoo | August 24, 2023

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Four poster presentations provided detailed and new data on the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes, and improvements in patient reported outcomes from the initial 16-week treatment period with rademikibart (formerly known as CBP-201) in patients with moderate-to-severe atopic dermatitis (AD) in the pivotal CN002 trial in China SAN DIEGO and TAICANG, China, July 10, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB)

Yahoo | July 10, 2023

Read More 'CNTB' Stories Here

CNTB Price Returns

1-mo -20.73%
3-mo -46.72%
6-mo -32.29%
1-year -48.41%
3-year N/A
5-year N/A
YTD -25.10%
2022 -83.15%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!